Enhancer-dependent chromatin rosette

An enhancer-dependent chromatin rosette is a specialized, three-dimensional (3D) loop-like DNA structure that physically clusters a gene’s active enhancer with multiple core regulatory elements and its target promoter. This structural framework serves two main purposes: maximizing gene expression and shielding the gene from gene-silencing machinery.

The discovery of the chromatin rosette explained exactly why small CRISPR gene-therapy edits (like those used in the sickle cell disease drug Casgevy) are capable of permanently shutting down a whole target gene. 

How the Rosette Functions

  • Multi-Way DNA Contact: Instead of a simple single-loop connection between one enhancer and one promoter, the DNA folds into a flower-like “rosette” shape. The enhancer acts as the central hub, drawing in multiple surrounding DNA regulatory segments simultaneously.
  • Epigenetic Insulation: The tight rosette fold creates a physical barrier (an “insulated neighborhood”). This structural wall permits high-level transcription and blocks nearby repressive Polycomb proteins from entering and applying silencing epigenetic marks. 
  • Dependence on eRNAs: The formation and structural integrity of this rosette rely entirely on enhancer RNAs (eRNAs). These are non-coding RNA molecules transcribed directly from the enhancer sequence that act as a structural glue to stabilize the 3D loops. 

The Real-World Example: BCL11A and Sickle Cell Disease

The primary model used to identify the rosette is the BCL11A gene. BCL11A is the cellular “switch” that shuts off fetal hemoglobin production and turns on adult hemoglobin. 

  • In normal blood cells: The BCL11A enhancer generates eRNAs, forming a robust chromatin rosette. This structure keeps BCL11A highly active, which successfully keeps fetal hemoglobin turned off. 
  • During gene therapy: CRISPR makes a precise cut in the enhancer. This slight sequence disruption stops the production of eRNAs, causing the entire 3D rosette to collapse. Without the protective rosette, repressive proteins rush in, silences BCL11A, and safely flips the switch back on to make therapeutic fetal hemoglobin. 

Cutting the BCL11A enhancer using CRISPR therapy disrupts its function by destroying its three-dimensional DNA architecture, which depends heavily on eRNAs.

Here is exactly how this process works at the molecular level:

  • The Chromatin Rosette Structure: In healthy adult red blood cell precursors, the intact BCL11A enhancer folds into a complex, multi-loop 3D structure known as an enhancer-dependent chromatin rosette. This structure holds the DNA in a way that provides “epigenetic insulation,” keeping the BCL11A gene highly active.
  • The Role of eRNAs: The transcription of this enhancer region produces specific eRNAs. These eRNAs are absolutely essential for the physical integrity of the chromatin rosette because they facilitate the loading of cohesin complexes (like NIPBL-dependent cohesin) that lock the 3D loops in place. 
  • The CRISPR Cut: When CRISPR-Cas9 (or similar nuclease) cuts this enhancer (often by targeting GATA1 binding sites), it alters the DNA sequence and prevents it from properly transcribing the eRNAs.
  • The Downstream Effect: Without the eRNAs, cohesin can no longer properly bind to the region. This causes the rosette structure to collapse. Once the protective 3D structure unfolds, the BCL11A gene is exposed to repressive proteins that silence its expression. 

Because BCL11A is a master repressor of fetal hemoglobin, disabling this enhancer means the gamma-globin genes are no longer silenced, ultimately producing therapeutic levels of fetal hemoglobin (HbF) to treat sickle cell disease and beta-thalassemia. 

Knowing that the rosette relies on eRNA molecules means scientists do not necessarily have to cut a patient’s DNA to treat genetic diseases. Researchers are actively developing antisense oligonucleotides (ASOs) to target and destroy the eRNA directly. This collapses the chromatin rosette and may achieve the same curative effects without using CRISPR, offering a cheaper, non-heritable approach to gene therapy.